Dynamic range of focus recovery in presbyopes after laser scleral microporation
While considered by many to be a “normal process of aging,” the loss of the dynamic focusing function of the eye, presbyopia, is a progressive disease of ocular aging. Presbyopia affects approximately 1.8 billion people globally.1 Estimated global annual productivity losses are approximately 0.037% of the global gross domestic
product in presbyopic adults less than 65 years of age.2
This socioeconomic issue is particularly problematic in developing countries where people are less likely to find visual correction.As people depend upon glasses or bifocals to perform near tasks, there is a decrease in health-related quality of life (HRQOL) and an increase in the risk of ocular diseases. Presbyopia is correlated with ocular rigidity, glaucoma, ocular hypertension, dysfunctional lens syndrome, age-related macular degeneration and cataracts, which can contribute to the effects of aging on ocular tissues.3
Explore More Articles
Laser scleral microporation: Unique method to treat presbyopia goes back to basics
Laser scleral microporation is a unique therapeutic solution for presbyopia that goes back to basics, rejuvenating the eye and restoring the natural dynamic mechanism of accommodation and disaccommodation. “Nature frequently develops dynamic processes, which work well for most individuals for the first 40 or 50 years of life but then, because of changes in the intrinsic …
read moreARVO LIVE: AI revolution in ophthalmology
Ophthalmology Times® talked with AnnMarie Hipsley, DPT, PhD, about 3D finite element model used to understand more about the biomechanics of accommodation and dis-accommodation as it relates to functions for visual function as well as aqueous hydrodynamics at this year’s ARVO meeting.
read moreAce Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
read more